Measurement of Blood Gene Transcripts Defines PRRT Therapeutic Efficacy Abstract #1228

Introduction: PRRT is an effective therapy for NETs since the majority over-express SSRs. Typically, well or moderately differentiated NETs (G1/G2) are treated. Imaging and CgA are used to evaluate response but both RECIST criteria and CgA have limitations.
Aim(s): Assess efficacy of a multi analyte algorithmic (MAAA) blood gene transcript test and CgA in defining PRRT efficacy.
Materials and methods: NETs (n=32), M: F 22:10, median age 67, bronchial: n=8, GEP-NET: n=22, CUP: n=2 were evaluated. 19/32 were G1/G2, 19/29 were FDG+ve and 24/32 had progressive disease (PD). Status was assessed clinically and with imaging (RECIST). Cumulative Lu-PRRT activity was 4.6-27.8 GBq, median 18.5. Transcript analysis was by qRT-PCR and ELISA for CgA (EuroDiagnostica). The MAAA NETest mathematically delineates disease activity risk: scale 0-100%; minimal <20%, low: 20-47%, high >47%.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei

To read results and conclusion, please login ...

Further abstracts you may be interested in

#316 Utilization of Gene Network Graph Topology with Inference Relevance Analysis Delineates G Protein-coupled Receptor Pathways and CREB Targets in Small Intestinal Neuroendocrine Neoplasia
Introduction: Despite an increasing incidence, a paucity of biological information has led to major limitations in identification of plausible therapeutic targets for small intestinal neuroendocrine tumors (SINETs)
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Giovanni Paganelli
#949 An Analysis of Toxicity after Peptide Receptor Radionuclide Therapy (PRRT) in 807 Patients: Determination of the Limited Predictive Role of Clinical Factors
Introduction: PRRT with 90Y-octreotide (Y) and 177Lu-octreotate (Lu) is well-tolerated.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Lisa Bodei
Authors: Bodei L, Kidd M, Grana C, Severi S, ...
Keywords: NET, PRRT, risk, toxicity
#1190 Blood Gene Transcript Analysis Predicts 68Ga- SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status
Introduction: Limitations of biomarkers and imaging are a concern in the identification of NET status and therapy response.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Kidd M, Modlin I, Drozdov I, ...
#1195 Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.
Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Keywords: Biomarker, SSA